SEARCH

SEARCH BY CITATION

References

  • Ascierto, M.L., Kmieciak, M., Idowu, M.O., Manjili, R., Zhao, Y., Grimes, M., Dumur, C., Wang, E., Ramakrishnan, V., Wang, X.Y., Bear, H.D., Marincola, F.M. & Manjili, M.H. (2012) A signature of immune function genes associated with recurrence-free survival in breast cancer patients. Breast Cancer Research and Treatment, 131, 871880.
  • Atanackovic, D., Arfsten, J., Cao, Y., Gnjatic, S., Schnieders, F., Bartels, K., Schilling, G., Faltz, C., Wolschke, C., Dierlamm, J., Ritter, G., Eiermann, T., Hossfeld, D.K., Zander, A.R., Jungbluth, A.A., Old, L.J., Bokemeyer, C. & Kröger, N. (2007) Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. Blood, 109, 11031112.
  • Bao, L., Dunham, K. & Lucas, K. (2011) MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing. Cancer Immunology, Immunotherapy, 60, 12991307.
  • Barlogie, B., Tricot, G., Anaissie, E., Shaughnessy, J., Rasmussen, E., Van Rhee, F., Fassas, A., Zangari, M., Hollmig, K., Pineda-Roman, M., Lee, C., Talamo, G., Thertulien, R., Kiwan, E., Krishna, S., Fox, M. & Crowley, J. (2006) Thalidomide and hematopoietic-cell transplantation for multiple myeloma. New England Journal of Medicine, 354, 10211030.
  • Bellucci, R., Wu, C.J., Chiaretti, S., Weller, E., Davies, F.E., Alyea, E.P., Dranoff, G., Anderson, K.C., Munshi, N.C. & Ritz, J. (2004) Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens. Blood, 103, 656663.
  • Bellucci, R., Alyea, E.P., Chiaretti, S., Wu, C.J., Zorn, E., Weller, E., Wu, B., Canning, C., Schlossman, R., Munshi, N.C., Anderson, K.C. & Ritz, J. (2005) Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor. Blood, 105, 39453950.
  • Chim, C.S., Liang, R., Fung, T.K., Choi, C.L. & Kwong, Y.L. (2007) Epigenetic dysregulation of the death-associated protein kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway in multiple myeloma. Journal of Clinical Pathology, 60, 664669.
  • Condomines, M., Hose, D., Raynaud, P., Hundemer, M., De Vos, J., Baudard, M., Moehler, T., Pantesco, V., Moos, M., Schved, J., Rossi, J., Reme, T., Goldschmidt, H. & Klein, B. (2007) Cancer/testis genes in multiple myeloma: expression patterns and prognosis value determined by microarray analysis. The Journal of Immunology, 178, 33073315.
  • Coral, S., Sigalotti, L., Altomonte, M., Engelsberg, A., Colizzi, F., Cattarossi, I., Maraskovsky, E., Jager, E., Seliger, B. & Maio, M. (2002) 5-aza-2 ‘-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. Clinical Cancer Research, 8, 26902695.
  • Coral, S., Sigalotti, L., Colizzi, F., Spessotto, A., Nardi, G., Cortini, E., Pezzani, L., Fratta, E., Fonsatti, E., Di Giacomo, A.M., Nicotra, M.R., Natali, P.G., Altomonte, M. & Maio, M. (2006) Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: immunotherapeutic implications. Journal of Cellular Physiology, 207, 5866.
  • Corral, L., Haslett, P., Muller, G., Chen, R., Wong, L., Ocampo, C.J., Patterson, R.T., Stirling, D.I. & Kaplan, G. (1999) Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. The Journal of Immunology, 163, 380386.
  • Cruz, C.R., Gerdemann, U., Leen, A.M., Shafer, J.A., Ku, S., Tzou, B., Horton, T.M., Sheehan, A., Copeland, A., Younes, A., Rooney, C.M., Heslop, H.E. & Bollard, C.M. (2011) Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4. Clinical Cancer Research, 17, 70587066.
  • Davies, F., Raje, N., Hideshima, T., Lentzsch, S., Young, G., Tai, Y., Lin, B., Podar, K., Gupta, D., Chauhan, D., Treon, S.P., Richardson, P.G., Schlossman, R.L., Morgan, G.J., Muller, G.W., Stirling, D.I. & Anderson, K.C. (2001) Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood, 98, 210216.
  • De Lerma Barbaro, A., De Ambrosis, A., Banelli, B., Li Pira, G., Aresu, O., Romani, M., Ferrini, S. & Accolla, R.S. (2008) Methylation of CIITA promoter IV causes loss of HLA-II inducibility by IFN-gamma in promyelocytic cells. International Immunology, 20, 14571466.
  • Durie, B.G., Harousseau, J.L., Miguel, J.S., Durie, B.G., Harousseau, J.L., Miguel, J.S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., Ludwig, H., Gahrton, G., Beksac, M., Crowley, J., Belch, A., Boccadaro, M., Cavo, M., Turesson, I., Joshua, D., Vesole, D., Kyle, R., Alexanian, R., Tricot, G., Attal, M., Merlini, G., Powles, R., Richardson, P., Shimizu, K., Tosi, P., Morgan, G. & Rajkumar, S.V. (2006) International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia, 20, 14671473.
  • Fonsatti, E., Nicolay, H.J., Sigalotti, L., Calabrò, L., Pezzani, L., Colizzi, F., Altomonte, M., Guidoboni, M., Marincola, F.M. & Maio, M. (2007) Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2'-deoxycytidine in cutaneous melanoma: immunotherapeutic implications. Clinical Cancer Research, 13, 33333338.
  • Goodyear, O., Agathanggelou, A., Novitzky-Basso, I., Siddique, S., McSkeane, T., Ryan, G., Vyas, P., Cavenagh, J., Stankovic, T., Moss, P. & Craddock, C. (2010) Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood, 116, 19081918.
  • Guo, Z., Hong, J., Irvine, K., Chen, A.G., Spiess, P.J., Liu, Y., Zeng, G., Wunderlich, J.R., Nguyen, D.M., Restifo, N.P. & Schrump, D.S. (2006) De novo induction of a cancer/testis antigen by 5-aza-2 ‘-deoxycytidine augments adoptive immunotherapy in a murine tumor model RID A-5713-2008. Cancer Research, 66, 11051113.
  • Hayashi, T., Hideshima, T., Akiyama, M., Podar, K., Yasui, H., Raje, N., Kumar, S., Chauhan, D., Treon, S.P., Richardson, P. & Anderson, K.C. (2005) Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. British Journal of Haematology, 128, 192203.
  • Hofmann, O., Caballero, O.L., Stevenson, B.J., Chen, Y.T., Cohen, T., Chua, R., Maher, C.A., Panji, S., Schaefer, U., Kruger, A., Lehvaslaiho, M., Carninci, P., Hayashizaki, Y., Jongeneel, C.V., Simpson, A.J., Old, L.J. & Hide, W. (2008) Genome-wide analysis of cancer/testis gene expression. Proceedings of the National Academy of Sciences of the USA, 105, 2042220427.
  • Hunder, N.N., Wallen, H., Cao, J., Hendricks, D.W., Reilly, J.Z., Rodmyre, R., Jungbluth, A., Gnjatic, S., Thompson, J.A. & Yee, C. (2008) Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. New England Journal of Medicine, 358, 26982703.
  • Jungbluth, A., Ely, S., DiLiberto, M., Niesvizky, R., Williamson, B., Frosina, D., Chen, Y., Bhardwaj, N., Chen-Kiang, S., Old, L.J. & Cho, H.J. (2005) The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. Blood, 106, 167174.
  • Kiziltepe, T., Hideshima, T., Catley, L., Raje, N., Yasui, H., Shiraishi, N., Okawa, Y., Ikeda, H., Vallet, S., Pozzi, S., Ishitsuka, K., Ocio, E.M., Chauhan, D. & Anderson, K.C. (2007) 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells. Molecular Cancer Therapeutics, 6, 17181727.
  • Klebanoff, C.A., Khong, H.T., Antony, P.A., Palmer, D.C. & Restifo, N.P. (2005) Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends in Immunology, 26, 111117.
  • Kmieciak, M., Basu, D., Payne, K.K., Toor, A., Yacoub, A., Wang, X., Smith, L., Bear, H.D. & Manjili, M.H. (2011a) Activated NKT cells and NK cells render T cells resistant to myeloid-derived suppressor cells and result in an effective adoptive cellular therapy against breast cancer in the FVBN202 transgenic Mouse. The Journal of Immunology, 187, 708717.
  • Kmieciak, M., Payne, K.K., Idowu, M.O., Grimes, M.M., Graham, L., Ascierto, M., Wang, E., Wang, X., Bear, H.D. & Manjili, M. (2011b) Tumor escape and progression of HER-2/neu negative breast cancer under immune pressure. Journal of Translational Medicine, 9, 35.
  • LeBlanc, R., Hideshima, T., Catley, L., Shringarpure, R., Burger, R., Mitsiades, N., Mitsiades, C., Cheema, P., Chauhan, D., Richardson, P.G., Anderson, K.C. & Munshi, N.C. (2004) Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood, 103, 17871790.
  • Lecoutre, B., Derzko, G. & Grouin, J.M. (1995) Bayesian predictive approach for inference about proportions. Statistics in Medicine, 14, 10571063.
  • Lim, S.Y., Laxmanan, S., Stuart, G. & Ghosh, S.K. (2001) Anti-lymphoma immunity: relative efficacy of peptide and recombinant DNA vaccine. Cancer Detection and Prevention, 25, 470478.
  • Martinez-Garcia, E., Popovic, R., Min, D.J., Sweet, S.M.M., Thomas, P.M., Zamdborg, L., Heffner, A., Will, C., Lamy, L., Staudt, L.M., Levens, D.L., Kelleher, N.L. & Licht, J.D. (2011) The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood, 117, 211220.
  • McLarnon, A., Piper, K.P., Goodyear, O.C., Arrazi, J.M., Mahendra, P., Cook, M., Clark, F., Pratt, G., Craddock, C. & Moss, P.A.H. (2010) CD8(+) T-cell immunity against cancer-testis antigens develops following allogeneic stem cell transplantation and reveals a potential mechanism for the graft-versus-leukemia effect. Haematologica, 95, 15721578.
  • Meklat, F., Li, Z., Wang, Z., Zhang, Y., Zhang, J., Jewell, A. & Lim, S.H. (2007) Cancer-testis antigens in haematological malignancies. British Journal of Haematology, 136, 769776.
  • Miklos, D.B., Kim, H.T., Miller, K.H., Guo, L., Zorn, E., Lee, S.J., Hochberg, E.P., Wu, C.J., Alyea, E.P., Cutler, C., Ho, V., Soiffer, R.J., Antin, J.H. & Ritz, J. (2005) Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood, 105, 29732978.
  • Moreno-Bost, A., Szmania, S., Stone, K., Garg, T., Hoerring, A., Szymonifka, J., Shaughnessy, J., Barlogie, B., Prentice, H.G. & Van Rhee, F. (2011) Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103. Cytotherapy, 13, 618628.
  • Natsume, A., Wakabayashi, T., Tsujimura, K., Shimato, S., Ito, M., Kuzushima, K., Kondo, Y., Sekido, Y., Kawatsura, H., Narita, Y. & Yoshida, J. (2008) The DNA demethylating agent 5-aza-2'-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma. International Journal of Cancer, 122, 25422553.
  • Nojima, M., Maruyama, R., Yasui, H., Suzuki, H., Maruyama, Y., Tarasawa, I., Sasaki, Y., Asaoku, H., Sakai, H., Hayashi, T., Mori, M., Imai, K., Tokino, T., Ishida, T., Toyota, M. & Shinomura, Y. (2009) Genomic screening for genes silenced by DNA methylation revealed an association between RASD1 inactivation and dexamethasone resistance in multiple myeloma. Clinical Cancer Research, 15, 43564364.
  • Rapoport, A.P., Stadtmauer, E.A., Aqui, N., Badros, A., Cotte, J., Chrisley, L., Veloso, E., Zheng, Z., Westphal, S., Mair, R., Chi, N., Ratterree, B., Pochran, M.F., Natt, S., Hinkle, J., Sickles, C., Sohal, A., Ruehle, K., Lynch, C., Zhang, L., Porter, D.L., Luge, S., Guo, C., Fang, H., Blackwelder, W., Hankey, K., Mann, D., Edelman1, R., Frasch, C., Levine, B.L., Cross, A. & June, C.H. (2005) Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nature Medicine, 11, 12301237.
  • Rapoport, A.P., Stadtmauer, E.A., Aqui, N., Vogl, D., Chew, A., Fang, H., Janofsky, S., Yager, K., Veloso, E., Zheng, Z., Milliron, T., Westphal, S., Cotte, J., Huynh, H., Cannon, A., Yanovich, S., Akpekl, G., Tan, M., Virts, K., Ruehle, K., Harris, C., Phillip, S., Vonderheide, R.H., Levine, B.L. & June, C.H. (2009) Rapid Immune Recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of costimulated autologous T cells. Clinical Cancer Research, 15, 44994507.
  • Shlomchik, W.D. (2007) Graft-versus-host disease. Nature reviews. Immunology, 7, 340352.
  • Simpson, A.J., Caballero, O.L., Jungbluth, A., Chen, Y.T. & Old, L.J. (2005) Cancer/testis antigens, gametogenesis and cancer. Nature Reviews Cancer, 5, 615625.
  • Sloand, E.M., Kim, S., Maciejewski, J.P., Van Rhee, F., Chaudhuri, A., Barrett, J. & Young, N.S. (2000) Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo. Blood, 95, 22692274.
  • Tatetsu, H., Ueno, S., Hata, H., Yamada, Y., Takeya, M., Mitsuya, H., Tenen, D.G. & Okuno, Y. (2007) Down-regulation of PU.1 by methylation of distal regulatory elements and the promoter is required for myeloma cell growth. Cancer Research, 67, 53285336.
  • Van Rhee, F., Szmania, S., Zhan, F., Gupta, S.K., Pomtree, M., Lin, P., Batchu, R.B., Moreno, A., Spagnoli, G., Shaughnessy, J. & Tricot, G. (2005) NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood, 105, 39393944.
  • Wang, Z., Zhang, Y., Liu, H., Salati, E., Chiriva-Internati, M. & Lim, S.H. (2003) Gene expression and immunologic consequence of SPAN-Xb in myeloma and other hematologic malignancies. Blood, 101, 955960.